What the trial found
Merck and Moderna presented new data showing their personalized cancer vaccine reduced the chance of melanoma coming back. The trial enrolled patients who had surgery to remove their tumors. Half received the vaccine plus an immunotherapy drug called Keytruda; the other half received Keytruda alone. Over the follow-up period, fewer patients in the vaccine group saw their cancer return. The companies called the results encouraging and said the full data will be shared at a medical conference. The data covers a follow-up period of more than two years, and the benefit appeared early and persisted across patient groups. Side effects were mostly mild, including fatigue and injection-site reactions, and were similar to those seen in earlier studies.
How the vaccine works
The vaccine is made for each patient individually. After surgery, scientists sequence the tumor and identify mutations unique to the cancer. Those mutations are used to build a vaccine that trains the immune system to spot and destroy cells carrying them. It is a personalized approach that turns the body's own defenses against the disease, and it is designed to be combined with standard immunotherapy. Each dose is manufactured within weeks of surgery, and the process has been refined so it can be scaled to thousands of patients.
What comes next
Melanoma is among the deadliest skin cancers, and recurrence is a major fear for patients. If the vaccine wins approval, it would join a growing toolbox of immunotherapies. The companies are already testing the same platform against lung, pancreatic, and other cancers. Researchers caution that mid-stage results do not guarantee success in larger trials, but the direction is clear: vaccines may soon become a standard part of cancer care. Regulators will review the data, and a confirmatory trial is already being planned. If approved, the vaccine would be offered alongside standard treatment rather than replacing it.